中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2013年
17期
1051-1054
,共4页
梁秀菊%楚慧丽%王俊%毕经旺
樑秀菊%楚慧麗%王俊%畢經旺
량수국%초혜려%왕준%필경왕
多西他赛%晚期卵巢癌%腹腔热灌注%热疗
多西他賽%晚期卵巢癌%腹腔熱灌註%熱療
다서타새%만기란소암%복강열관주%열료
docetaxel%advanced ovarian cancer%intraperitoneal chemotherapy%hyperthermia
目的:观察多西他赛联合腹腔内顺铂热灌注化疗加热疗治疗晚期卵巢癌的疗效与不良反应。方法:无法手术及复发晚期卵巢癌患者83例,随机分成两组:热疗组42例,行多西他赛静脉化疗后即刻行腹腔内顺铂热灌注化疗并加腹部局部射频热疗;对照组41例,单纯给予多西他赛静脉化疗加腹腔内顺铂热灌注化疗。结果:热疗组和对照组的总有效率分别是81.0%和58.1%,其中总有效率显著提高(P<0.05),腹水控制率分别为78.3%和66.7%,CA125下降率分别为84.2%和61.5%(P<0.05),主要不良反应为消化道不良反应及骨髓抑制,无显著性差异。结论:多西他赛联合顺铂腹腔内灌注加热疗明显提高晚期卵巢癌的疗效,不增加不良反应,值得进一步推广。
目的:觀察多西他賽聯閤腹腔內順鉑熱灌註化療加熱療治療晚期卵巢癌的療效與不良反應。方法:無法手術及複髮晚期卵巢癌患者83例,隨機分成兩組:熱療組42例,行多西他賽靜脈化療後即刻行腹腔內順鉑熱灌註化療併加腹部跼部射頻熱療;對照組41例,單純給予多西他賽靜脈化療加腹腔內順鉑熱灌註化療。結果:熱療組和對照組的總有效率分彆是81.0%和58.1%,其中總有效率顯著提高(P<0.05),腹水控製率分彆為78.3%和66.7%,CA125下降率分彆為84.2%和61.5%(P<0.05),主要不良反應為消化道不良反應及骨髓抑製,無顯著性差異。結論:多西他賽聯閤順鉑腹腔內灌註加熱療明顯提高晚期卵巢癌的療效,不增加不良反應,值得進一步推廣。
목적:관찰다서타새연합복강내순박열관주화료가열료치료만기란소암적료효여불량반응。방법:무법수술급복발만기란소암환자83례,수궤분성량조:열료조42례,행다서타새정맥화료후즉각행복강내순박열관주화료병가복부국부사빈열료;대조조41례,단순급여다서타새정맥화료가복강내순박열관주화료。결과:열료조화대조조적총유효솔분별시81.0%화58.1%,기중총유효솔현저제고(P<0.05),복수공제솔분별위78.3%화66.7%,CA125하강솔분별위84.2%화61.5%(P<0.05),주요불량반응위소화도불량반응급골수억제,무현저성차이。결론:다서타새연합순박복강내관주가열료명현제고만기란소암적료효,불증가불량반응,치득진일보추엄。
Objective:This study aimed to observe the curative effect and adverse reaction of docetaxel combined with intraperitoneal cisplatin chemotherapy and hyperthermia treatment of advanced ovarian cancer. Methods:A total of 83 patients with inoperable and recurrent advanced ovarian cancer were randomly divided into two groups:hyperthermia group and control group. The hyperthermia group consisted of 42 cases of docetaxel chemotherapy immediately treated with intraperitoneal cisplatin chemotherapy combined with abdominal local hyperthermia. The control group included 41 cases of docetaxel chemotherapy and intraperitoneal cisplatin chemotherapy treatment only. Results:The total efficiencies of the hyperthermia treatment group and the control group were 81%and 58.1%, respectively, which showed that the total efficiency significantly improved (P<0.05). The ascite control rates were 78.3%and 66.7%and CA125 decreased by 84.2%and 61.5%for the hyperthermia and control groups, respectively. The main adverse reactions were gastrointestinal reaction and bone marrow suppression. However, differences were not statistically significant. Conclusion:Docetaxel combined with cisplatin intraperitoneal perfusion hyperthermia significantly improved the curative effect on advanced ovarian cancer without increasing toxicity, which indicates that it is a treatment worth popularizing.